WO2004082397A1 - Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems - Google Patents
Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems Download PDFInfo
- Publication number
- WO2004082397A1 WO2004082397A1 PCT/DK2004/000187 DK2004000187W WO2004082397A1 WO 2004082397 A1 WO2004082397 A1 WO 2004082397A1 DK 2004000187 W DK2004000187 W DK 2004000187W WO 2004082397 A1 WO2004082397 A1 WO 2004082397A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adsorbent
- bio
- column
- molecule
- process according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/001—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from waste materials, e.g. kitchen waste
- A23J1/005—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from waste materials, e.g. kitchen waste from vegetable waste materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/08—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from eggs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1807—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using counter-currents, e.g. fluidised beds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
Definitions
- the invention relates to an industrial scale chromatographic process for fractionation and isolation of bio-molecules from fluids, e.g. proteins from milk and whey in a cost-effective manner.
- the process allows for processing large volumes of fluid in a short time and for improved adsorbent efficiency by means of operating the process at high temperature and high flow rate.
- the concentration of lactoferrin in bovine skimmed milk is usually low, typically between 80-200 mg/l depending on e.g. the pasteurisation process and other pre- treatment history of the skimmed milk.
- WO 02/096215 relates to a method for fractionating lactoferrin from milk or whey using flow rates about 200 to 900 cm/hr. Furthermore, fractionation of immunoglobulins is of interest.
- WO 98/08603 relates to a method for isolation of immunoglobulins. Conventionally, these methodologies have been carried out using temperatures in the range of about 10°C. In an industrial environment for production of bio-molecules, e.g. for production of food or food ingredients and bio-pharmaceuticals there is an indispensable need for careful control of the microbiology in order to avoid contamination or breakdown of the target biomolecule product.
- the biomolecule target is further a delicate substance, e.g. an enzyme or other protein or peptide, a polynucleotide, a viral particle or other easily degradable substance that only have limited stability at elevated temperatures. Therefore there is a general need to keep processing temperatures below 10-15 degrees Celsius since such low temperatures generally inhibit microbial growth while at the same time minimise the risk of deterioration of the target biomolecule.
- a delicate substance e.g. an enzyme or other protein or peptide, a polynucleotide, a viral particle or other easily degradable substance that only have limited stability at elevated temperatures. Therefore there is a general need to keep processing temperatures below 10-15 degrees Celsius since such low temperatures generally inhibit microbial growth while at the same time minimise the risk of deterioration of the target biomolecule.
- Chromatographic adsorption processes are generally known to be able to accommodate a very broad range of processing temperatures and it is well-known in the art that increased operating temperatures improve the mass transfer kinetics of a chromatographic system. Thus high operating temperatures are often applied in analytical HPLC columns for the analysis of low molecular weight compounds.
- the present investigators report herein a method for significant improvement of the productivity of chromatographic processes of industrial scale by providing means for operating the chromatographic processes with very high flow rates and still maintain highly efficient adsorption and integrity of the biomolecule under temperature conditions that inhibit microbial growth. Thus, such processes may allow for more cost effective fractionation and/or isolation of bio-molecules of interest.
- Patent 5,596,082 discloses an industrial process for isolation of lactoperoxidase and lactoferrin from milk and milk products with packed bed chromatography using a strong cation exchanger (SP Sepharose Big Beads from Amersham Biosciences).
- SP Sepharose Big Beads from Amersham Biosciences.
- the chromatographic beads described for the process have a mean particle size in the range of 100- 300 microns and working flow rates in the range of 2000 - 3000 cm/hr may be used.
- the present invention relates to a chromatographic process capable of processing very large volumes of bio-molecule-containing fluids in a short time and capable of providing high productivity, while still achieving high purity and integrity of the biological molecule isolated by the process. This may be achieved by operating the chromatographic processes in a combination of high flow rates and high temperatures.
- a primary aspect the invention relates to a general process for fractionating and/or isolation of one or more bio-molecule(s) from a bio-molecule-containing fluid, the process comprising the steps of:
- a volume of said bio-molecule-containing fluid having a temperature of at least 40°C to a chromatographic column, such as an expanded bed adsorption column, comprising an adsorbent, at a linear flow rate of at least 1.500 cm/hour;
- One object of the present invention is to provide an improved process for industrial-scale fractionation and/or isolation of proteins, such as lactoferrin, from suitable body fluids or fluids derived therefrom including milk and whey, DETAILED DESCRIPTION OF THE INVENTION
- the present investigators provide herein evidence for that the combination of high operating temperature and high flow rate applied upon loading of the bio-molecule- containing fluids onto a chromatographic column and significantly improves the adsorptive capacity and the productivity of the adsorbent of the chromatographic column, while at the same time inhibit the microbial growth and keep the biomolecule intact.
- operating a chromatographic process at a temperature of 50°C instead of the conventional 10°C results in doubling of the adsorbent capacity of the adsorbent, i.e. the amount (g) of Lactoferrin adsorbed to 1 I of adsorbent was doubled.
- the invention relates to a process for fractionating and/or isolation of one or more bio-molecule(s) from a bio-molecule-containing fluid comprising the steps of:
- a volume of said bio-molecule-containing fluid having a temperature of at least 40°C to a chromatographic column, such as preferably an expanded bed column, comprising an adsorbent, said chromatographic column is operated with a linear flow rate of at least 1.500 cm/hour;
- bio-molecule is intended to mean any molecule and entity that is obtainable from biological origin having a molecular weight of at least 1000 Daltons.
- the bio-molecule may be obtained by use of synthetically means, gene technology and/or fermentation.
- the bio-molecule may be different to that of the biological origin because of derivatising of the bio-molecule.
- bio-molecule is meant to encompass bio-molecules that are obtainable from biological origin and derivatives thereof.
- bio-molecules are peptides, proteins, lipids, hormones, lipoproteins, polysaccharides, polynucleotides, bio-polymers or mixtures thereof.
- bio-molecule also encompasses entities obtainable from biological origin having a molecular weight of at least 20,000 D, e. g. DNA (plasmid DNA, chromosomal DNA, virus DNA), RNA such as virus RNA, or virus cells and constituents thereof, even bacteria cells and constituents thereof.
- DNA plasmid DNA, chromosomal DNA, virus DNA
- RNA such as virus RNA
- bio-molecule is also meant to include cell constituents and ceils.
- the process acquires practical importance for bio-molecules of higher molecular weight.
- the one or more bio-molecule(s) has/have a molecular weight of at least 1500 Daltons, more preferably of at least 2000 Daltons.
- the process of the invention may be applicable for a broad variety of bio-molecules as long as any adsorbent capable of binding the bio-molecule of interest is available. Therefore, in embodiments of the invention, the one or more bio-molecule(s) is/are selected from peptides, proteins, lipids, lipoproteins, polysaccharides, polynucleotides, plasmids, , DNA, RNA, viral particles, cell constituents, cells or combinations thereof.
- the one or more bio-molecules is/are selected from: o Proteins such as lactoferrin, immunoglobulins, ⁇ -lactoglobulin, ⁇ -lactalbumin, lactoperoxidase, patatin, protease inhibitors and other proteins from potatoes, enzymes, such as lysozym. o Lipids such as phospholipids from milk. o Polysaccharides, such as starches (maize and potato starch), and pectin's such as chitosans.
- Bio-molecule-containinq fluid The process according to the present invention is targeted, at least in part, for industrial or large-scale fractionation processes where large volumes must be handled.
- fluids containing bio-molecules in low content such as fluids that otherwise may be discharged, e.g. process water containing interesting bio-molecules, but in too low content in order to attract any commercial interest.
- bio-molecule-containing fluids that contain high amounts of bio-molecules are not anticipated by the present invention, and may constitute further interesting embodiments.
- bio-molecule-containing fluid is intended to denote a fluid of biological origin or derived therefrom, which comprises at least one or more bio-molecule within the context of this invention to be fractionated, partially or wholly purified or isolated on an industrial or large scale.
- such fluids include body fluids or fluids derived therefrom including milk, skimmed milk, whey or other milk derived fluids; blood or fluids derived therefrom; plasma or fluids derived therefrom; serum or fluids derived therefrom; lymph or fluids derived therefrom; urine or fluids derived therefrom; egg white or fluids derived therefrom; or egg yolk or fluids derived therefrom.
- the bio-molecule-containing fluid is denoted to include fermentation fluids; waste water; process water; plant extracts, such as fruit derived fluids; animal tissue extracts, such as fish derived fluids, animal blood plasma or animal serum; synthesis mixtures; and/or fluids derived therefrom.
- the bio-molecule-containing fluid is selected from body fluids, fermentation fluids, wastewater, process water, plant extracts, animal tissue extracts, animal blood plasma, animal serum, synthesis mixtures and/or fluids derived therefrom.
- the bio-molecule-containing fluid is process water from the food and/or feed industry, e.g. process water from the production of starches, e.g. potato starch and/or maize starch.
- the bio-molecule-containing fluid is waste water comprising undesirable organic molecules, such as toxins, allergens, pesticides in that the waste water need to be purified from the containment of such undesirable organic molecules before being released to the environment or used for preparation of drinking water.
- the bio-molecule-containing fluid is selected from the group comprising of milk, skimmed milk, whey or any other milk derived fluids.
- the bio-molecule-containing fluid may before being loaded to a chromatographic column need an adjustment in pH depending on the protein of interest, the ligand chemistry, and the type of bio-molecule-containing fluid.
- the bio-molecule-containing fluid is pH adjusted prior to being applied to the adsorbent column in order to facilitate the capture of bio-molecule such as a protein by the adsorbent.
- This pH may be adjusted to a pH value selected in the entire pH range, preferably from pH 2-13, more preferably from pH 3-11.
- the chromatographic column to be used may be any kind suitable for either EBA (Expanded Bed Adsorption) or any non-packed bed adsorption system a combination thereof.
- the chromatographic column may be used in either a batch system or in a continuos system.
- the chromatographic column is an expanded bed adsorption column and in still other embodiments, the chromatographic column is a stirred tank adsorption column.
- chromatographic column relates to any kind of container, which can be supplied with at least one inlet and at least one outlet, for the application of the bio-moiecule-containing fluid to the column and subsequent elution of one or more bio-molecule of interest.
- EBA technology generally can work efficiently with non-clarified fluids makes it attractive to implement for the isolation and fractionation of bio-molecules from fluids such as milk, whey fermentation fluids and process water.
- EBA may offer a robust process comprising fewer steps resulting in increased yields and an improved process economy.
- EBA columns Due to the expansion of the adsorbent bed during execution of an EBA process, EBA columns can be scaled up to industrial scale without any significant considerations to increased backpressure or breakdown of the process due to clogging of the system. This is often seen as a problem when using packed bed columns.
- the process may be specific applicable to industrial scale systems.
- the chromatographic column is a large- scale chromatographic column comprising at least 10 I of sedimented adsorbent, as may be determined as the amount (litre) of adsorbent settled when operating the column without flow.
- the chromatographic column is a large-scale chromatographic column comprising from about 50 to 100 I of sedimented adsorbent.
- the amount of sedimented adsorbent is from about 100 to 1000 I, more preferably from about 200 to 900 I, most preferably from about 300 to 800 I.
- the chromatographic column has a diameter of at least 10 cm, preferably of at least 20 cm, more preferably in the range of from about 50 cm to 200 cm, such as 100 to 150 cm.
- Temperature As mentioned conventional methodologies within the field of fractionating and isolating bio-molecules often uses temperatures about 15 °C or lower, such as 10°C.
- one objection of the present invention is to utilise higher temperatures in chromatographic processes for isolation of bio-molecules, although high temperatures may under normal conditions negatively affect temperature sensitive bio-molecules. For instance enzymes may loose their enzymatic capacity upon being exposed to high temperatures, such as temperatures above 40°C.
- the chromatographic column is operated at temperatures of at least 40°C, such as at least 45 °C, e.g. at least 50°C, such as at least 55 °C, e.g. at least 60°C, such as at least 65 °C, e.g. at least 70°C.
- an upper limit may exist, such as about 80°C when considering some bio-molecules that has tolerance for high temperatures, but may not resist temperatures above 80°C.
- low molecular weight biomolecules, such as peptides may tolerate high temperatures, such as temperatures in the range of 40-100°C, such as in the range of 45-100°C, e.g.
- the chromatographic column is operated at temperatures up to 100 °C.
- the column and the adsorbent inside the column may be heated to the desired operating temperature before applying the biomolecule-containing fluid. Flushing the column with hot water or a buffer solution having the desired temperature may efficiently perform this temperature adjustment.
- the column may be insulated or even heat-jacketed in order to maintain a constant temperature during the column operation. In many instances this may not be necessary, however, because the high flow of biomolecule containing fluid through the column is adequate to maintain the desired temperature.
- the temperature of the bio-molecule- containing fluid is between 50 and 70 °C.
- linear flow rates of from about 1.500 to 12.000 cm/hr may be applicable during loading of the bio-molecule-containing fluid to the chromatographic column.
- the linear flow rate may be operated within the range from 1.800 to 10.000 cm/hr, such as within the range of 2.000 to 10.000 cm/hr, such as typically at linear flow rates of about 3000 to 7000 cm/hr.
- the utilisation of higher flow rates allows for loading high volumes of bio-molecule- containing fluids within a shorter time than conventionally possible. However, this may depend on the size of column adapted. In current suitable embodiments of the invention, the volume to be applied onto the column is from about 2-3500 l/min.
- the efficiency of the process as defined herein may be expressed by the volume of bio-containing fluids that can be applied to 1 litre of adsorbent per hour.
- the volume applied per litre of adsorbent in one hour is at least 50 I, preferably at least 100 1, and more preferably at least 150 l/min such as at least 200 l/min.
- the present process which operates at high temperatures, such as above 45°C, allows for operating the chromatographic column with a pressure, as measured over the entire chromatographic column, of at most 10 bar.
- the pressure is of at most 9, 8, 7, 6 or 5 bar, preferably of at most 4 bar, most preferably of at most 3 bar such as of at most 2.5 bar.
- Adsorbent relates to the entire bed present in the chromatographic column and the term “adsorbent particle” are used interchangeably with the term “particle” and relates to the individual single particles, which makes up the adsorbent.
- adsorbent is meant to characterize any suitable adsorbent used in chromatographic processes such as adsorbents suitable for ion-exchange chromatography, protein A and Protein G affinity chromatography, other affinity chromatography, hydrophobic chromatography, reverse phase chromatography, thiophilic adsorption chromatography and mixed mode adsorption chromatography and the like.
- the degree of expansion may be determined as H/H0, where HO is the height of the bed in packed bed mode (without flow) and H is the height of the bed in the expanded bed mode obtained when applying a flow of liquid to the column.
- H/H0 is in the range of 1.0-20, such as 1.0-10, e.g. 1.0-6, such as 1.2-5, e.g. 1.5-4 such as 4-6, such as 3-5, e.g. 3-4 such as 4-6.
- the degree of expansion H/HO is at most 1.0, such as at most 1.5, e.g. at most 2, such as at most 2.5, e.g. at most 3, such as at most 3.5, e.g. at most 4, such as at most 4.5, e.g. at most 5, such as at most 5.5, e.g. at most 6, such as at most 10, e.g. at most 20.
- the particle size analysis performed and referred to throughout the description and the examples is based on an computerised image analysis of the bead population giving the number of particles at any given particle diameter in relation to the total number of particles analysed in the specific measurement. Typically the total number of particles analysed will be in the range of 250-500 particles.
- These particle size data may be transferred into the volume percent represented by each particle size by a routine mathematical transformation of the data, calculating the volume of each bead and relating this to the total volume occupied by all beads counted in the measurement.
- the particle size distribution according to the invention is preferably defined so that more than 90% of the particles are present in a size ranging between 20% to 500% of the mean particle diameter. More preferable, 90% of the particles are present in a size ranging between 50-200% of the mean particle diameter, most preferable between 50-150% of the mean particle diameter.
- the level of clarification of the feed stream also affects the pressure drop.
- Traditional packed beds work as depth filters that can clog, resulting in increased pressure drop unless the feed is thoroughly clarified.
- the density of the EBA adsorbent particle is found to be highly significant for the applicable flow rates in relation to the maximal degree of expansion of the adsorbent bed possible inside a typical EBA column (e.g. H/HO max 3-5) and must be at least 1.3 g/mL, more preferably at least 1.5 g/mL, still more preferably at least 1.8 g/mL, even more preferably at least 2.0 g/mL, most preferably at least 2.3 g/mL in order to enable a high productivity of the process and an acceptable degree of bed expansion.
- the process of the invention may be operated with use of high flow rates, while still achieving high productivity and efficient adsorption of bio-molecules to the adsorbent.
- This may, at least in part, be due to the limitation in the mean particle diameter of the adsorbent particle.
- the adsorbent particle has a mean particle size of at most 200 ⁇ m.
- the mean particle size is at most 150 ⁇ m, particularly at most 120 ⁇ m, more particularly at most 100 ⁇ m, even more particularly at most 90 ⁇ m, even more particularly at most 80 ⁇ m, even more particularly at most 70 ⁇ m.
- the adsorbent particle has a mean particle size in the range of 40-150 ⁇ m, such as 40-120 ⁇ m, e.g. 40-100, such as 40-75, e.g. 40-50 ⁇ m.
- mean particle size is meant the particle size that 50% of the particles in the adsorbent has, as determined by the number of particles.
- the adsorbent is made of particles, wherein 50% of the number of particles has a particle size of at most 200 ⁇ m, particularly at most 175, 150, 120, 100, 90, 80 or at most 70 ⁇ m.
- the particle size as referred to herein relates to the longest distance as can be measured on the particle.
- the particle density is at least 1.6 g/mL, more preferably at least 1.9 g/mL.
- the density must be at least 1.8 g/mL or more preferable at least 2.0 g/mL.
- the average particle diameter is less than 75 ⁇ m the density must be at least 2.0 g/mL, more preferable at least 2.3 g/mL and most preferable at least 2.5 g/mL.
- the adsorbent particle has a density of at least 1.5 g/ml, such as at least 1.8 g/ml, e.g. at least 2.0 g/ml, such as at least 2.5 g/ml, such as at least 2.6 g/ml, e.g. at least 3.0 g/ml, such as at least 3.5 g/ml, e.g. at least 4.0 g/ml, such as at least 5 g/ml, e.g. at least 7 g/ml, such as at least 10 g/ml, e.g. at least 15 g/ml.
- the density of an adsorbent particle is meant to describe the density of the adsorbent in its fully solvated (e.g. hydrated) state as opposed to the density of a dried adsorbent.
- the adsorbent particle used according to the invention must be at least partly permeable to the bio-molecular substance to be isolated in order to ensure a significant binding capacity in contrast to impermeable particles that can only bind the target molecule on its surface resulting in relatively low bind ing capacity.
- the adsorbent particle may be of an array of different structures, composit :ions and shapes.
- the adsorbent particle may be constituted by for example a porous h igh density material such as porous ceramic beads, porous glass beads and porous zirconium oxide or a high density conglomerate as described below.
- the adsorbent particles may be constituted of a number of chemically derivatised porous materials having the necessary density and binding capacity to operate at the given flow rates per se.
- the particles are either of the conglomerate type, as described in WO 92/00799, having at least two non-porous cores surrounded by a porous material, or of the pellicular type having a single non-porous core surrounded by a porous material.
- the term "conglomerate type” relates to a particle of a particulate material, which comprises beads of core material of different types and sizes, held together by the polymeric base matrix, e.g. an core particle consisting of two or more high density particles held together by surrounding agarose (polymeric base matrix).
- pellicular type relates to a composite of particles, wherein each particle consists of only one high density core material coated with a layer of the porous polymeric base matrix, e.g. a high density stainless steel bead coated with agarose.
- At least one high density non-porous core relates to either a pellicular core, comprising a single high density non-porous particle or it relates to a conglomerate core comprising more that one high-density non-porous particle.
- the adsorbent particle comprises a high-density non-porous core with a porous material surrounding the core, and said porous material optionally comprising a ligand at its outer surface.
- core relates to the non-porous core particle or core particles present inside the adsorbent particle.
- the core particle or core particles may be incidental distributed within the porous material and is not limited to be located in the centre of the adsorbent particle.
- the non-porous core constitutes typically of at most 50% of the total volume of the adsorbent particle, such as at most 40%, preferably at most 30%.
- suitable non-porous core materials are inorganic compounds, metals, heavy metals, elementary non-metals, metal oxides, non metal oxides, metal salts and metal alloys, etc. as long as the density criteria above are fulfilled.
- core materials are metal silicates metal borosilicates; ceramics including titanium diboride, titanium carbide, zirconium diboride, zirconium carbide, tungsten carbide, silicon carbide, aluminium nitride, silicon nitride, titanium nitride, yttrium oxide, silicon metal powder, and molybdenum disilide; metal oxides and sulfides, including magnesium, aluminium, titanium, vanadium, chromium, zirconium, hafnium, manganese, iron, cobalt, nickel, copper and silver oxide; non-metal oxides; metal salts, including barium sulfate; metallic elements, including tungsten, zirconium, titanium, hafnium, vanadium,
- the porous material is a polymeric base matrix used as a means for covering and keeping multiple (or a single) core materials together and as a means for binding the adsorbing ligand.
- the polymeric base matrix may be sought among certain types of natural or synthetic organic polymers, typically selected from i) natural and synthetic polysaccharides and other carbohydrate based polymers, including agar, alginate, carrageenan, guar gum, gum arabic, gum ghatti, gum tragacanth, karaya gum, locust bean gum, xanthan gum, agaroses, celluloses, pectins, mucins, dextrans, starches, heparins, chitosans, hydroxy starches, hydroxypropyl starches, carboxymethyl starches, hydroxyethyl celluloses, hydroxypropyl celluloses, and carboxymethyl celluloses; ii) synthetic organic polymers and monomers resulting in polymers, including acrylic polymers, polyamides, polyimides, polyesters, polyethers, polymeric vinyl compounds, polyalkenes, and substituted derivatives thereof, as well as copolymers comprising more than one such polymer functional
- a preferred group of polymeric base matrices are polysaccharides such as agarose. From a productivity point of view it is important that the adsorbent is able to bind a high amount of the bio-molecule per volume of the adsorbent.
- the preferred shape of a single adsorbent particle is substantially spherical.
- the overall shape of the particles is, however, normally not extremely critical, thus, the particles can have other types of rounded shapes, e.g. ellipsoid, droplet and bean forms.
- Preparation of the particulate material according to the invention may be performed by various methods known per se (e.g. by conventional processes known for the person skilled in the art, see e.g. EP 0 538 350 Bl or WO 97/17132.
- block polymerisation of monomers e.g. by block polymerisation of monomers; suspension polymerisation of monomers; block or suspension gelation of gel-forming materials, e.g. by heating and cooling (e.g. of agarose) or by addition of gelation "catalysts" (e.g. adding a suitable metal ion to alginates or carrageenans); block or suspension cross-linking of suitable soluble materials (e.g.
- silica polymers by acidification of silica solutions (e.g. block or suspension solutions); mixed procedures e.g. polymerisation and gelation; spraying procedures; and fluid bed coating of density controlling particles; cooling emulsions of density controlling particles suspended in polymeric base matrices in heated oil solvents; or by suspending density controlling particles and active substance in a suitable monomer or copolymer solution followed by polymerisation.
- a particulate material comprising agarose as the polymeric base matrix and steel beads as the core material is obtained by heating a mixture of agarose in water (to about 95°C), adding the steel beads to the mixture and transferring the mixture to a hot oil (e.g. vegetable oils), emulsifying the mixture by vigorous stirring (optionally by adding a conventional emulsifier) and cooling the mixture.
- a hot oil e.g. vegetable oils
- the particle size i.e. the amount of polymeric base matrix (here: agarose) which is incorporated in each particle can be adjusted by varying the speed of the mixer and the cooling process.
- the particle size distribution may be further defined by sieving and/or fluid bed elutriation.
- the porous matrix such as polymer agarose
- the adsorbent comprises a ligand with affinity to proteins.
- the ligand constitutes the adsorbing functionality of the adsorbent media or the polymeric backbone of the adsorbent particle has a binding functionality incorporated per se.
- Well-known ligand chemistries such as cation exchangers, e.g. sulphonic acid, have been proven to be efficient tools for purification of whey proteins such as lactoferrin and lactoperoxidase. These proteins are positively charged, even at neutral pH, and selective interaction with a cation exchanger can be obtained. Other proteins require more sophisticated binding interaction with the ligand in order to obtain a selective adsorption.
- affinity ligands like the chargeable moieties, may be linked to the base matrix by methods known to the person skilled in the art, e.g. as described in "Immobilized Affinity Ligand Techniques" by Hermanson et al., Academic Press, Inc., San Diego, 1992.
- the polymeric base matrix may be derivatised to function as an active substances in the procedures of activation or derivatisation.
- materials comprising hydroxyl, amino, amide, carboxyl or thiol groups may be activated or derivatised using various activating chemicals, e.g.
- chemicals such as cyanogen bromide, divinyl sulfone, epichlorohydrin, bisepoxyranes, dibromopropanol, glutaric dialdehyde, carbodiimides, anhydrides, hydrazines, periodates, benzoquinones, triazines, tosylates, tresylates, and diazonium ions.
- the adsorbent carries ligands for adsorption of the b ⁇ omolecular substances in a concentration of at least 20 nM, such as at least 30 mM or at least 40 mM, preferably at least 50 mM and most preferably at least 60 mM.
- a subset of adsorbents may be characterised in terms of their binding capacity to bovine serum albumin (BSA).
- BSA bovine serum albumin
- This subset of adsorbents are typically those comprising a ligand selected from the group consisting of i) ligands comprising aromatic or heteroaromatic groups (radicals) of the following types as functional groups: benzoic acids such as 2- aminobenzoic acids, 3-aminobenzoic acids, 4-aminobenzoic acids, 2-mercaptobenzoic acids, 4-amino-2-chlorobenzoic acid, 2-amino-5-chlorobenzoic acid, 2-amino-4- chlorobenzoic acid, 4-aminosaiicylic acids, 5-aminosalicylic acids, 3,4-diaminobenzoic acids, 3,5-diaminobenzoic acid, 5-aminoisophthalic acid, 4-aminophthalic acid; cinnamic acids such as hydroxy-cinnamic
- M is agarose
- SP1 is derived from vinyl sulfone
- L is 4-aminobenzoic acid
- amino- benzoic acids like 2-amino-benzoic acid, 2-mercapto-benzoic acid, 3-aminobenzoic acid, 4- aminobenzoic acid, 4-amino-2-chlorobenzoic acid, 2-amino-5-chlorobenzoic acid, 2-amino- 4-chlorobenzoic acid, 4-aminosalicylic acids, 5-aminosalicylic acids, 3,4-diaminobenzoic acids, 3,5-diaminobenzoic acid, 5-5-aminoisophthalic acid, 4-aminophthalic acid; ii) ligands comprising 2-hydroxy-cinnamic acids, 3-hydroxy-cinnamic acid and 4-hydroxy-cinnamic acid
- a ligand selected from benzimidazoles such as 2-mercapto-benzimidazol and 2-mercapto-5-nitro-benzimidazol; benzothiazols such as 2-amino-6-nitrobenzothiazol, 2-mercaptobenzothiazol and 2-mercapto-6- ethoxybenzothiazol; benzoxazols such as 2-mercaptobenzoxazol;and v) ligands chosen from the group of thiophenols such as thiophenol and 2-aminothiophenol.
- the adsorbents typically have a dynamic binding capacity of at least 10 g of biomolecular substance per litre, more preferably at least 20 g per litre, still more preferable at least 30 g per litre when tested according to the process conditions used in the relevant application.
- the binding capacity of the adsorbent may be determined in terms of its binding capacity to bovine serum albumin (BSA).
- BSA bovine serum albumin
- the binding capacity is typically such that at least lOg/L of BSA binds according to test Method A.
- Method A is a method used for determination of the bovine albumin binding capacity of selected adsorbents consisting of the following process:
- Bovine serum albumin solution pH 4.0 (BSA pH 4.0): Purified bovine serum albumin (A 7906, Sigma, USA) is dissolved to a final concentration of 2 mg/ml in 20 mM sodium citrate pH 4.0. Adsorbents are washed with 50 volumes of 20 mM sodium citrate pH 4.0 and drained on a suction filter.
- a sample of 1.0 ml suction drained adsorbent is placed in a 50 ml test tube followed by the addition of 30 ml of BSA, pH 4.0.
- test tube is then closed with a stopper and the suspension incubated on a roller mixer for 2 hours at room temperature (20-25 °C).
- the test tube is then centrifuged for 5 min. at 2000 RPM in order to sediment the adsorbent completely.
- the supernatant is then isolated from the adsorbent by pipetting into a separate test tube, avoiding the carry-over of any adsorbent particles and filtered through a small non-adsorbing 0.2 ⁇ m filtre (Millipore, USA). Following this a determination of the concentration of non-bound BSA in the supernatant is performed by measuring the optical density (OD) at 280 nm on a spectrophotometer.
- OD optical density
- the washing liquid is water e.g. tap water, demineralised water, water produced by reverse osmosis or distilled water, aqueous buffers or other aqueous solutions with high ionic strength.
- the washing liquid is the sample collected at the column outlet during loading of the column with the bio-molecule-containing fluid; the so-called run through fraction.
- the washing liquid may be the collected "run-through sample" which essentially consist of the whey constituents that are not adsorbed to the column.
- any bio-molecule-containing fluid that has been loaded to an expanded bed column and collected as the "run through fraction" can be applied as long as the "run though fraction" has the required ionic strength.
- the flow rate used for the washing steps involved is selected from the ranges outlined previously for conventional methodologies. These are generally much lower than the linear flow-rate used when loading the bio-molecule-containing fluid onto the column. Elution
- the one or more bio-molecule(s) of interest is/are released from the adsorbent using an eluent such as a buffer or any other solution capable of changing for example the pH within the column and which produces a generally clear and concentrated solution of the one or more bio-molecule(s).
- an eluent such as a buffer or any other solution capable of changing for example the pH within the column and which produces a generally clear and concentrated solution of the one or more bio-molecule(s).
- eluents depend on the type of adsorbent and the elution may be performed by any method conventionally described and known in the art.
- the elution of the adsorbed protein is performed with a solution, typically selected from the group consisting of dilute base, dilute acid, and water.
- a solution typically selected from the group consisting of dilute base, dilute acid, and water.
- the solution is dilute so as to minimise the amount of salt and other unwanted substances present in the eluted product.
- the dilute acid or base used for elution of the biomolecule has a salt concentration of less than 50 mM, preferably less than 30 mM, even more preferable less than 20 mM.
- the determination of the salt concentration is performed directly on the eluate fraction containing the protein or proteins to be isolated without additional dilution of the eluate fraction.
- Common, low cost and non-toxic acids and bases are applicable. Specifically preferred are the bases sodium hydroxide (NaOH), potassium hydroxide (KOH), calcium hydroxide (Ca(OH) 2 ), ammonium hydroxide (NH 4 OH).
- the flow rate used for the elution step or steps involved is selected from the ranges outlined previously for applying the protein- containing mixture to the adsorbent column.
- Non-pasteurised skimmed milk with pH 6.6 was obtained from a local dairy company.
- the adsorbent is based on agarose with tungsten carbide particles incorporated, density of approximately 2.9 g/ml, particle size in the range of 40-200 ⁇ m with a mean particle size of 80 ⁇ m, strong cation exchanger comprising sulfonic acid groups.
- the column was packed with a sedimented (packed) bed height (H 0 ) of 15 cm of adsorbent
- lactoferrin concentration of lactoferrin in the eluate was determined by Single Radial Immunodiffusion (RID) using goat anti-bovine lactoferrin from Bethyl Laboratories inc. (1 ⁇ l per cm 2 ) as described in Scand. 3. Immunol. Vol. 17, Suppl. 10, 41-56, 1983. The concentration was calculated from a standard curve produced with well know concentrations of lactoferrin from Sigma (cat. no. L 9507).
- the actual flow rate through the columns is 100 l/hr/l of adsorbent.
- Example 2 Isolation of lactoferrin from non-pasteurised skimmed milk using expanded bed chromatography at linear flow rates of 1,500, 2,100 or 3,000 cm/hr at 50°C.
- the column was packed with 15 cm of adsorbent (10.6 I) and equilibrated with demineralised water at 16°C or 50°C respectively.
- the column was washed with aqueous buffer pH 6.5 containing 25 mM of sodium citrate and 0.30 M of sodium chloride. Lactoferrin was then eluted using a solution of 20mM sodium hydroxide.
- Sweet whey was obtained from a local dairy company, the pH was 6.3.
- the adsorbent is based on agarose with tungsten carbide particles incorporated, density of approximately 2.9 g/ml, particle size in the range of 40-200 ⁇ m with a mean particle size of 80 ⁇ m.
- the adsorbent comprises a mixed mode ligand comprising an aromatic ring structure with a carboxylic acid substituent.
- the adsorbent binds molecules in the pH range of 3 to 6. The molecules are released by increasing the pH in the elution buffer to above 7.
- the column was packed with 15 cm of adsorbent (10.6 1) and equilibrated with demineralised water at 50°C.
- Non-bound material was washed out with demineralised water (290 I).
- the bound proteins were eluted in two steps.
- Step 1 50 mM adipic acid, 0.1 mg/ml SDS (sodium dodecylsulfate) pH 5.3 (275 I).
- Step 2 20 mM NaOH (117 I).
- Sample preparation 25 ⁇ l sample and 25 ⁇ l sample buffer Tris-Glycine Invitrogen (cat no.
- Tris (Sigma T138), 0.19 M Glycine (Merck 5001901000), 0.1 % SDS (Sodium dodecyl sulphate, JT Baker 2811) pH 8.6 was added.
- the non-pasteurised skimmed milk has an initial concentration of lactoferrin of 150 mg/l
- the table shows the resulting yield of lactoferrin obtained from the process operated with high loading linear flow rates of 4800 or of 6000 cm/hr, respectively.
- IgG immunoglobulin G
- Sweet whey was obtained from cheese production.
- the sweet whey was pumped through a heat exchanger to reach 40°C, 50°C, 55°C, 60°C and 65°C, respectively, before it was loaded onto the column. pH of the sweet whey was adjusted to 4.7 before being loaded onto the column.
- the column was packed with a sedimented bed height of 25cm of adsorbent (17.7 I) and then equilibrated with demineralised water to a temperature 40°C, 50°C, 55°C, 60°C and 65°C, respectively:
- the adsorbent was washed with 5 times of the column volume collected during loading of the whey (88.5 I). Then the pH in the whey was adjusted to pH 5.3 before used for washing. Following the first wash of the column with the above-mentioned collected whey (Flow through fraction), the column was washed with demineralised water (89 I). Finally, IgG was eluted from the adsorbent using 20 mM of sodium hydroxide (61 I).
- the concentration of IgG in the flow through fraction as well as in fluid collected during wash with demineralised water and elution with NaOH was determined by Single Radial Immunodiffusion (RID). Rabbit anti-bovine immunoglobuline from Dako Cytomation, Denmark (Cat. no. : Z247) was used (1 ⁇ l per cm2).
- the amount of IgG recovered in the different fractions was determined as the percentage of IgG found in each fraction in relation to the total loaded amount of IgG, which was set to 100%.
- Loading ratio between whey and adsorbent is 1:40 (40 litres of whey per litre of adsorbent, amounts to 1414 litre)
- results from SDS-PAGE shows that different proteins is present in eluates resulting from the experiments utilising 2.5 times and 5 times, respectively, of the column volume of sweet whey for the first wash of the adsorbent.
- ⁇ -lactoglobulin is present in the eluate resulting from the "2.5" experiment, whereas this protein is not detected when utilising 5 times the column volume of sweet whey as the washing liquid for the first wash of the adsorbent.
- An increase of the bed height from 25 to 50 cm decreases the amount of IgG in the flow through sample collected during loading of the whey onto the adsorbent with 10 %, which leads to a higher yield from the raw material.
- the amount of IgG recovered in the fraction collected as the flow through fraction upon loading the whey onto the adsorbent increases with the increasing loading ratios.
- the sweet whey was loaded onto the adsorbent using different linear flow rates: 1200 cm/hr, 1800 cm/hr and 2400 cm/hr, respectively:
- the amount of IgG in the "run through fraction" increases with increasing flow rates.
- the IgG-containing eluate from Example 7 was used.
- the process was performed with an expanded bed system at room temperature at a linear flow rate at 900 cm/hr.
- the pH of the IgG product was adjusted to pH 7.0 with 1 M hydrochloric acid before being loaded onto the column.
- the column was packed with a sedimented bed height of 50 cm of adsorbent (3.9 I) and equilibrated with 1 M NaOH and demineralised water.
- the concentration of BSA and IgG in the flow through fraction (IgG product) was determined by Single Radial Immunodiffusion (RID).
- Rabbit anti-bovine serum albumin from Dako Cytomation (Cat. no. : Z229) was used (0.75 ⁇ l per cm2).
- 5 Rabbit anti-bovine immunoglobulin from Dako Cytomation (Cat. no. : Z247) was used (1 ⁇ l per cm2).
- the amount of BSA and IgG in the flow through is defined as a percentage of BSA and IgG compared with the total load of BSA and IgG that equals a 100 %.
- the SDS-PAGE shows that 90 % of the BSA was removed from the IgG product using the above-mentioned weak anion exchanger.
- the purified IgG-fraction is estimated to have a 5 purity higher than 80 % with respect to IgG.
- Egg white was obtained from a local egg industry.
- Pre-treatment of the egg white For running the experiment at 50°C the egg white was pumped through a heat exchanger to reach 50°C before it was loaded onto the column.
- the pH of the egg white was adjusted to pH 7 with 1 M hydrochloric acid before being loaded onto the column.
- the column was packed with a sedimented bed height of 25cm of adsorbent (17.7 I) and equilibrated with demineralised water, at 50°C.
- the adsorbent was first washed with 50 mM of sodium chloride (177 I). Then, the lysozyme was eluted from the adsorbent using 20 mM sodium hydroxide (195 I).
- the activity of the lysozyme was determined using Micrococcus lysodeikticus cells, Sigma Chemicals, USA (Shugar, David. Biochimica et Biophysica Acta 1952, 8,302-309)
- the eluate contained 525 g of highly purified lysozyme.
- the yield of lysozyme was high approximately 100 %.
- the purity of the lysozyme was shown to be high, estimated to be higher than 90 % as demonstrated using SDS-PAGE.
- Potato juice was produced from washed potatoes. The potatoes were blended for 5 minutes, 30 ml of sodium sulphite was added per 2 kg of potatoes to prevent enzymatic browning of the juice. The blended potatoes were pressed through lOO ⁇ m nylon net and the juice was collected.
- the potato juice was pumped through a heat exchanger to reach 50°C before it was loaded onto the column.
- the pH of the juice was adjusted to pH 4.5 with 1 M hydrochloric acid before being loaded onto the column.
- the column was packed with a sedimented bed height of 65cm of adsorbent (46 I) and equilibrated with demineralised water, at 50°C.
- the adsorbent was washed with 10 mM sodium citrate pH 4.5 (322 I).
- the proteins were eluted from the adsorbent with 10 mM sodium hydroxide (230 I).
- the eluate was freeze-dried and the protein content was determined by Kjeldahl.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Dairy Products (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004222627A AU2004222627B2 (en) | 2003-03-21 | 2004-03-19 | Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems |
EP04721828A EP1605772B1 (en) | 2003-03-21 | 2004-03-19 | Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems |
DK04721828T DK1605772T3 (en) | 2003-03-21 | 2004-03-19 | Process for high throughput volumes in the fractionation of biomolecules by chromatographic systems |
NZ542956A NZ542956A (en) | 2003-03-21 | 2004-03-19 | Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems |
US10/548,403 US20070092960A1 (en) | 2003-03-21 | 2004-03-19 | Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems |
DE602004007250T DE602004007250T2 (en) | 2003-03-21 | 2004-03-19 | HIGH-SPEED HIGH-VOLUME PROCESS FOR THE FRACTIONATION OF BIOMOLECULES BY CHROMATOGRAPHIC SYSTEMS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300443 | 2003-03-21 | ||
DKPA200300443 | 2003-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004082397A1 true WO2004082397A1 (en) | 2004-09-30 |
Family
ID=33016788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2004/000187 WO2004082397A1 (en) | 2003-03-21 | 2004-03-19 | Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070092960A1 (en) |
EP (1) | EP1605772B1 (en) |
AT (1) | ATE365463T1 (en) |
AU (1) | AU2004222627B2 (en) |
DE (1) | DE602004007250T2 (en) |
DK (1) | DK1605772T3 (en) |
NZ (1) | NZ542956A (en) |
WO (1) | WO2004082397A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005121163A3 (en) * | 2004-06-07 | 2006-03-23 | Upfront Chromatography As | Isolation of plasma or serum proteins |
DE102006002249A1 (en) * | 2006-01-17 | 2007-07-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Process for obtaining a vegetable protein fraction, in particular for the production of vegetable ice cream |
EP1920662A1 (en) * | 2006-11-10 | 2008-05-14 | Coöperatie Avebe U.A. | Native potato protein isolates |
WO2008086811A1 (en) * | 2007-01-15 | 2008-07-24 | Upfront Chromatography A/S | Production of biofuel and protein from a raw material |
EP1994972A1 (en) * | 2007-05-15 | 2008-11-26 | Coöperatie AVEBE U.A. | Method and device for continuous chromatographic separations |
US20100298228A1 (en) * | 2007-11-01 | 2010-11-25 | Snow Brand Milk Products Co., Ltd. | Bone-reinforcing food material |
WO2012055986A1 (en) * | 2010-10-27 | 2012-05-03 | Philip Morris Products S.A. | Methods for capturing virus like particles from plants using expanded chromatography |
WO2015009400A1 (en) * | 2013-07-16 | 2015-01-22 | Mjn U.S. Holdings Llc | Expanded bed adsorption methods for isolation of basic milk proteins including lactoferrin |
US9220997B2 (en) | 2007-03-28 | 2015-12-29 | Dpx Holdings B.V. | Expanded bed column and disposable chromatography |
CN108179164A (en) * | 2018-02-08 | 2018-06-19 | 金华市铁骑士生物科技有限公司 | The method that polypeptide is extracted from degreasing protein breast supernatant |
WO2019201465A1 (en) | 2018-04-20 | 2019-10-24 | Propharma Group Europe B.V. | Method for separation with simulated moving bed |
US11753451B2 (en) | 2012-07-11 | 2023-09-12 | Coöperatie Avebe U.A. | Potato protein isolates |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2355664T3 (en) * | 2008-09-30 | 2014-10-06 | Upfront Chromatography As | Process for providing a beta-lactoglobulin product and an alpha-enriched whey protein isolate |
CN104109204B (en) * | 2013-04-16 | 2017-11-07 | 武汉禾元生物科技股份有限公司 | A kind of method that restructuring lactoferrin is isolated and purified from rice paddy seed |
DK201700721A1 (en) * | 2017-12-17 | 2019-06-27 | Upfront Chromatography A/S | Adsorbent comprising metal dioxide |
MX2023000510A (en) | 2020-07-20 | 2023-04-14 | Purolite China Co Ltd | Methods for chromatographic protein extraction and purification. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1363783A (en) * | 1971-11-09 | 1974-08-14 | Meggle J A Molkerei J A Meggle | Process for the production of a whey protein concentrate |
US5719053A (en) * | 1996-05-06 | 1998-02-17 | Primus Corporation | Chromatographic method for the identification and characterization of hemoglobin variants in blood |
US5986063A (en) * | 1998-07-31 | 1999-11-16 | Wisconsin Alumni Research Foundation | Isolating β-lactoglobulin and α-lactalbumin by eluting from a cation exchanger without sodium chloride |
WO1999065586A2 (en) * | 1998-06-18 | 1999-12-23 | Upfront Chromatography A/S | Expanded bed adsorption system |
WO2002096215A1 (en) * | 2001-06-01 | 2002-12-05 | Upfront Chromatography A/S | Fractionation of protein containing mixtures |
US6498236B1 (en) * | 1996-08-30 | 2002-12-24 | Upfront Chromatography A/S | Isolation of immunoglobulins |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0725800B2 (en) * | 1987-04-10 | 1995-03-22 | 雪印乳業株式会社 | Method for separating and purifying lactoferrin from milk using sulfate esterification product |
DK165090D0 (en) * | 1990-07-09 | 1990-07-09 | Kem En Tec As | CONLOMERATED PARTICLES |
WO1993013676A1 (en) * | 1992-01-15 | 1993-07-22 | Campina Melkunie B.V. | Process for isolating lactoferrin and lactoperoxidase from milk and milk products, and products obtained by such process |
US5837826A (en) * | 1995-02-27 | 1998-11-17 | Regents Of The University Of Minnesota | Protein adsorption by very dense porous zirconium oxide particles in expanded beds |
US20020104801A1 (en) * | 1998-04-06 | 2002-08-08 | Nicolas Voute | Small dense microporous solid support materials, their preparation,and use for purification of large macromolecules and bioparticles |
EP1165201B1 (en) * | 1999-03-26 | 2007-02-21 | Upfront Chromatography A/S | Particulate material for fluidised bed purification of bio-macromolecules such as plasmid dna, chromosomal dna, rna, viral dna, bacteria and viruses |
AU2001231527A1 (en) * | 2000-02-08 | 2001-08-20 | Upfront Chromatography A/S | Novel resin materials and their use for recovering proteins or peptides |
DE60131710T2 (en) * | 2000-08-24 | 2008-11-13 | Kaneka Corp. | Methods of adsorption and removal, and use of an adsorbent for endogenous cannabinoids |
-
2004
- 2004-03-19 AT AT04721828T patent/ATE365463T1/en not_active IP Right Cessation
- 2004-03-19 DK DK04721828T patent/DK1605772T3/en active
- 2004-03-19 WO PCT/DK2004/000187 patent/WO2004082397A1/en active IP Right Grant
- 2004-03-19 AU AU2004222627A patent/AU2004222627B2/en not_active Ceased
- 2004-03-19 EP EP04721828A patent/EP1605772B1/en not_active Expired - Lifetime
- 2004-03-19 DE DE602004007250T patent/DE602004007250T2/en not_active Expired - Lifetime
- 2004-03-19 NZ NZ542956A patent/NZ542956A/en not_active IP Right Cessation
- 2004-03-19 US US10/548,403 patent/US20070092960A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1363783A (en) * | 1971-11-09 | 1974-08-14 | Meggle J A Molkerei J A Meggle | Process for the production of a whey protein concentrate |
US5719053A (en) * | 1996-05-06 | 1998-02-17 | Primus Corporation | Chromatographic method for the identification and characterization of hemoglobin variants in blood |
US6498236B1 (en) * | 1996-08-30 | 2002-12-24 | Upfront Chromatography A/S | Isolation of immunoglobulins |
WO1999065586A2 (en) * | 1998-06-18 | 1999-12-23 | Upfront Chromatography A/S | Expanded bed adsorption system |
US5986063A (en) * | 1998-07-31 | 1999-11-16 | Wisconsin Alumni Research Foundation | Isolating β-lactoglobulin and α-lactalbumin by eluting from a cation exchanger without sodium chloride |
WO2002096215A1 (en) * | 2001-06-01 | 2002-12-05 | Upfront Chromatography A/S | Fractionation of protein containing mixtures |
Non-Patent Citations (1)
Title |
---|
ANSPACH F BIRGER ET AL: "Expanded-bed chromatography in primary protein purification", JOURNAL OF CHROMATOGRAPHY A, vol. 865, no. 1-2, 31 December 2000 (2000-12-31), pages 129 - 144, XP002285383, ISSN: 0021-9673 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005121163A3 (en) * | 2004-06-07 | 2006-03-23 | Upfront Chromatography As | Isolation of plasma or serum proteins |
US9624260B2 (en) | 2004-06-07 | 2017-04-18 | Therapure Biopharma Inc. | Process for isolation of plasma or serum proteins |
EP3127916A1 (en) * | 2004-06-07 | 2017-02-08 | Therapure Biopharma Inc. | Isolation of plasma or serum proteins |
US9428545B2 (en) | 2004-06-07 | 2016-08-30 | Therapure Biopharma Inc. | Process for isolation of plasma or serum proteins |
EP2277912A3 (en) * | 2004-06-07 | 2011-05-04 | Upfront Chromatography A/S | Isolation of plasma or serum proteins |
DE102006002249B4 (en) * | 2006-01-17 | 2010-12-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Process for obtaining a vegetable protein fraction, in particular for the production of vegetable ice cream |
DE102006002249A1 (en) * | 2006-01-17 | 2007-07-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Process for obtaining a vegetable protein fraction, in particular for the production of vegetable ice cream |
US8257772B2 (en) | 2006-01-17 | 2012-09-04 | Fraunhofer-Gesellschaft zur Föderung der angewandten Forschung e.V. | Method for obtaining a vegetable plant protein fraction, in particular for producing vegetable ice cream |
US8465911B2 (en) | 2006-11-10 | 2013-06-18 | Cooperatie Avebe U.A. | Native potato protein isolates |
EP1920662A1 (en) * | 2006-11-10 | 2008-05-14 | Coöperatie Avebe U.A. | Native potato protein isolates |
WO2008069650A1 (en) | 2006-11-10 | 2008-06-12 | Coöperatie Avebe U.A. | Native potato protein isolates |
WO2008086811A1 (en) * | 2007-01-15 | 2008-07-24 | Upfront Chromatography A/S | Production of biofuel and protein from a raw material |
US8815551B2 (en) | 2007-01-15 | 2014-08-26 | Upfront Chromatography A/S | Production of biofuel and protein from a raw material |
US9220997B2 (en) | 2007-03-28 | 2015-12-29 | Dpx Holdings B.V. | Expanded bed column and disposable chromatography |
EP1994972A1 (en) * | 2007-05-15 | 2008-11-26 | Coöperatie AVEBE U.A. | Method and device for continuous chromatographic separations |
US20100298228A1 (en) * | 2007-11-01 | 2010-11-25 | Snow Brand Milk Products Co., Ltd. | Bone-reinforcing food material |
US8420599B2 (en) * | 2007-11-01 | 2013-04-16 | Megmilk Snow Brand Co., Ltd. | Bone-reinforcing food material |
US9056894B2 (en) | 2010-10-27 | 2015-06-16 | Philip Morris Products S.A. | Methods for capturing virus like particles from plants using expanded bed chromatogrpahy |
JP2013544509A (en) * | 2010-10-27 | 2013-12-19 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | Method of capturing target particles from a mixture |
CN103228327B (en) * | 2010-10-27 | 2016-01-27 | 菲利普莫里斯生产公司 | Use expanded bed chromatography from plant, catch the method for virus-like particle |
US20130317197A1 (en) * | 2010-10-27 | 2013-11-28 | Philip Morris Products S.A. | Methods for capturing virus like particles from plants using expanded bed chromatogrpahy |
RU2606609C2 (en) * | 2010-10-27 | 2017-01-10 | Филип Моррис Продактс С.А. | Method (versions) for capturing particles of interest from mixture |
CN103228327A (en) * | 2010-10-27 | 2013-07-31 | 菲利普莫里斯生产公司 | Methods for capturing virus like particles from plants using expanded chromatography |
JP2017055766A (en) * | 2010-10-27 | 2017-03-23 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | Method for capturing particles of interest from mixture |
WO2012055986A1 (en) * | 2010-10-27 | 2012-05-03 | Philip Morris Products S.A. | Methods for capturing virus like particles from plants using expanded chromatography |
US11753451B2 (en) | 2012-07-11 | 2023-09-12 | Coöperatie Avebe U.A. | Potato protein isolates |
WO2015009400A1 (en) * | 2013-07-16 | 2015-01-22 | Mjn U.S. Holdings Llc | Expanded bed adsorption methods for isolation of basic milk proteins including lactoferrin |
US9661868B2 (en) | 2013-07-16 | 2017-05-30 | Mead Johnson Nutrition Company | Expanded bed adsorption methods for isolation of basic milk proteins including lactoferrin |
CN108179164A (en) * | 2018-02-08 | 2018-06-19 | 金华市铁骑士生物科技有限公司 | The method that polypeptide is extracted from degreasing protein breast supernatant |
WO2019201465A1 (en) | 2018-04-20 | 2019-10-24 | Propharma Group Europe B.V. | Method for separation with simulated moving bed |
Also Published As
Publication number | Publication date |
---|---|
EP1605772B1 (en) | 2007-06-27 |
DK1605772T3 (en) | 2007-10-29 |
ATE365463T1 (en) | 2007-07-15 |
AU2004222627B2 (en) | 2009-12-03 |
DE602004007250T2 (en) | 2008-02-28 |
AU2004222627A1 (en) | 2004-09-30 |
DE602004007250D1 (en) | 2007-08-09 |
NZ542956A (en) | 2007-11-30 |
EP1605772A1 (en) | 2005-12-21 |
US20070092960A1 (en) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1552752B1 (en) | Fractionation of protein containing mixtures | |
AU2002316806A1 (en) | Fractionation of protein containing mixtures | |
AU2004222627B2 (en) | Method for high throughput volumes in the fractionation of bio-molecules by chromatographic systems | |
EP2355664B1 (en) | A method for providing a alpha-lactoglobulin product and a beta-enriched whey protein isolate | |
Roy et al. | Current trends in affinity-based separations of proteins/enzymes | |
EP3021682B1 (en) | Expanded bed adsorption methods for isolation of basic milk proteins including lactoferrin | |
US5780593A (en) | Method of isolating biomolecules by ion exchange | |
WO2016023553A1 (en) | Method for separating alpha-lactalbumin and beta-lactoglobulin | |
EP2115000A1 (en) | Isolation and separation of minimally denatured potato proteins and peptides | |
Nath et al. | Emerging purification and isolation | |
AU4464699A (en) | Process for recovering growth factors, or a composition containing one or more growth factors, from milk or a milk derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004721828 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004222627 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004222627 Country of ref document: AU Date of ref document: 20040319 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004222627 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 542956 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2004721828 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007092960 Country of ref document: US Ref document number: 10548403 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10548403 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004721828 Country of ref document: EP |